Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open‐label, dose‐escalation safety study
Identifieur interne : 002F81 ( Main/Exploration ); précédent : 002F80; suivant : 002F82Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open‐label, dose‐escalation safety study
Auteurs : Richard M. Trosch [États-Unis] ; Charles H. Adler [États-Unis] ; Eric J. Pappert [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-07-15.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Aged, Anti-Dyskinesia Agents (therapeutic use), BoNT‐B, Bontoxilysin, Botulinum Toxins (therapeutic use), Dose-Response Relationship, Drug, Drug Evaluation, Female, Hemifacial Spasm (drug therapy), Hemifacial spasm, Human, Humans, Male, Middle Aged, Nervous system diseases, Pain Measurement, Safety, Time Factors, Treatment Outcome, botulinum toxin type B, hemifacial spasm, myobloc.
- MESH :
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- drug therapy : Hemifacial Spasm.
- Adult, Aged, Dose-Response Relationship, Drug, Drug Evaluation, Female, Humans, Male, Middle Aged, Pain Measurement, Time Factors, Treatment Outcome.
Abstract
Ojbective: Evaluate the safety of botulinum toxin type B (BoNT‐B) in subjects with hemifacial spasm (HFS). Methods: This open‐label, sequential dose‐escalation study evaluated BoNT‐B in subjects with HFS. Eligible subjects were enrolled and received a single injection of one of four sequential BoNT‐B doses (100, 200, 400, or 800 U). Following injection, subjects were evaluated in person at Weeks 2 and 8 and by phone at Weeks 1, 4, and 10 and every 2 weeks thereafter until benefit was lost. Safety was assessed by adverse events (AEs), vital signs and clinical laboratory evaluation. The severity of HFS was assessed using a patient social impairment visual analog scale (VAS), subject severity of contraction VAS, the HFS physician assessment, and subject HFS frequency and severity assessment. Results: Nineteen predominately Caucasian (92%) and female (67%) subjects (aged 36–80 years) with HFS participated in this study. Subjects remained in the study an average of 88 days (range of 41–332 days) after receiving a single dose of BoNT‐B. No deaths, serious AEs or AEs leading to trial discontinuation occurred during the study period. Two subjects in the 400 U dose group requested early withdrawal, whereas all other subjects completed the study. A reduction in HFS severity was observed in subjects treated with doses of 200 U or more. Improvements in subject HFS assessments tended to return to baseline values by 8 weeks following injection. Conclusion: BoNT‐B was well‐tolerated and reduced HFS severity in subjects who received injections of 200 to 800 U. Additional investigation is necessary to confirm the findings from this open‐label study. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21435
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001475
- to stream Istex, to step Curation: 001475
- to stream Istex, to step Checkpoint: 001A89
- to stream PubMed, to step Corpus: 002608
- to stream PubMed, to step Curation: 002608
- to stream PubMed, to step Checkpoint: 002938
- to stream Ncbi, to step Merge: 001D51
- to stream Ncbi, to step Curation: 001D51
- to stream Ncbi, to step Checkpoint: 001D51
- to stream Main, to step Merge: 003F03
- to stream PascalFrancis, to step Corpus: 001621
- to stream PascalFrancis, to step Curation: 001700
- to stream PascalFrancis, to step Checkpoint: 001767
- to stream Main, to step Merge: 004357
- to stream Main, to step Curation: 002F81
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open‐label, dose‐escalation safety study</title><author><name sortKey="Trosch, Richard M" sort="Trosch, Richard M" uniqKey="Trosch R" first="Richard M." last="Trosch">Richard M. Trosch</name></author><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name></author><author><name sortKey="Pappert, Eric J" sort="Pappert, Eric J" uniqKey="Pappert E" first="Eric J." last="Pappert">Eric J. Pappert</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0031C2596E57DCF413CDFCB1550694C928F1D5EA</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21435</idno><idno type="url">https://api.istex.fr/document/0031C2596E57DCF413CDFCB1550694C928F1D5EA/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001475</idno><idno type="wicri:Area/Istex/Curation">001475</idno><idno type="wicri:Area/Istex/Checkpoint">001A89</idno><idno type="wicri:doubleKey">0885-3185:2007:Trosch R:botulinum:toxin:type</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17588242</idno><idno type="wicri:Area/PubMed/Corpus">002608</idno><idno type="wicri:Area/PubMed/Curation">002608</idno><idno type="wicri:Area/PubMed/Checkpoint">002938</idno><idno type="wicri:Area/Ncbi/Merge">001D51</idno><idno type="wicri:Area/Ncbi/Curation">001D51</idno><idno type="wicri:Area/Ncbi/Checkpoint">001D51</idno><idno type="wicri:Area/Main/Merge">003F03</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:07-0391075</idno><idno type="wicri:Area/PascalFrancis/Corpus">001621</idno><idno type="wicri:Area/PascalFrancis/Curation">001700</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001767</idno><idno type="wicri:doubleKey">0885-3185:2007:Trosch R:botulinum:toxin:type</idno><idno type="wicri:Area/Main/Merge">004357</idno><idno type="wicri:Area/Main/Curation">002F81</idno><idno type="wicri:Area/Main/Exploration">002F81</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open‐label, dose‐escalation safety study</title><author><name sortKey="Trosch, Richard M" sort="Trosch, Richard M" uniqKey="Trosch R" first="Richard M." last="Trosch">Richard M. Trosch</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>The Parkinson's Disease and Movement Disorders Center, 26400 W, Southfield, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Pappert, Eric J" sort="Pappert, Eric J" uniqKey="Pappert E" first="Eric J." last="Pappert">Eric J. Pappert</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Neurology and Solstice Neurosciences, Inc, University of Texas Health Science Center, San Antonio, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-07-15">2007-07-15</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">9</biblScope><biblScope unit="page" from="1258">1258</biblScope><biblScope unit="page" to="1264">1264</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0031C2596E57DCF413CDFCB1550694C928F1D5EA</idno><idno type="DOI">10.1002/mds.21435</idno><idno type="ArticleID">MDS21435</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Anti-Dyskinesia Agents (therapeutic use)</term><term>BoNT‐B</term><term>Bontoxilysin</term><term>Botulinum Toxins (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Evaluation</term><term>Female</term><term>Hemifacial Spasm (drug therapy)</term><term>Hemifacial spasm</term><term>Human</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Pain Measurement</term><term>Safety</term><term>Time Factors</term><term>Treatment Outcome</term><term>botulinum toxin type B</term><term>hemifacial spasm</term><term>myobloc</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hemifacial Spasm</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Drug Evaluation</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pain Measurement</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term><term>Homme</term><term>Hémispasme facial</term><term>Système nerveux pathologie</term><term>Sécurité</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Ojbective: Evaluate the safety of botulinum toxin type B (BoNT‐B) in subjects with hemifacial spasm (HFS). Methods: This open‐label, sequential dose‐escalation study evaluated BoNT‐B in subjects with HFS. Eligible subjects were enrolled and received a single injection of one of four sequential BoNT‐B doses (100, 200, 400, or 800 U). Following injection, subjects were evaluated in person at Weeks 2 and 8 and by phone at Weeks 1, 4, and 10 and every 2 weeks thereafter until benefit was lost. Safety was assessed by adverse events (AEs), vital signs and clinical laboratory evaluation. The severity of HFS was assessed using a patient social impairment visual analog scale (VAS), subject severity of contraction VAS, the HFS physician assessment, and subject HFS frequency and severity assessment. Results: Nineteen predominately Caucasian (92%) and female (67%) subjects (aged 36–80 years) with HFS participated in this study. Subjects remained in the study an average of 88 days (range of 41–332 days) after receiving a single dose of BoNT‐B. No deaths, serious AEs or AEs leading to trial discontinuation occurred during the study period. Two subjects in the 400 U dose group requested early withdrawal, whereas all other subjects completed the study. A reduction in HFS severity was observed in subjects treated with doses of 200 U or more. Improvements in subject HFS assessments tended to return to baseline values by 8 weeks following injection. Conclusion: BoNT‐B was well‐tolerated and reduced HFS severity in subjects who received injections of 200 to 800 U. Additional investigation is necessary to confirm the findings from this open‐label study. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Arizona</li><li>Michigan</li><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Trosch, Richard M" sort="Trosch, Richard M" uniqKey="Trosch R" first="Richard M." last="Trosch">Richard M. Trosch</name></region><name sortKey="Adler, Charles H" sort="Adler, Charles H" uniqKey="Adler C" first="Charles H." last="Adler">Charles H. Adler</name><name sortKey="Pappert, Eric J" sort="Pappert, Eric J" uniqKey="Pappert E" first="Eric J." last="Pappert">Eric J. Pappert</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F81 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F81 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0031C2596E57DCF413CDFCB1550694C928F1D5EA
|texte= Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open‐label, dose‐escalation safety study
}}
| This area was generated with Dilib version V0.6.23. |  |